What is the biological half-life of spironolactone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Biological Half-Life of Spironolactone

Spironolactone has a short half-life of approximately 1.4 hours, but its active metabolites have much longer half-lives ranging from 13.8 to 16.5 hours, which accounts for its prolonged clinical effects. 1

Pharmacokinetics of Spironolactone

Parent Compound

  • Spironolactone itself has a mean half-life of only 1.4 hours 1
  • Peak plasma concentration is reached in approximately 2.6 hours 1
  • Food increases bioavailability by approximately 95.4% 1
  • Protein binding exceeds 90% 1

Active Metabolites

Spironolactone undergoes extensive metabolism to several active metabolites with significantly longer half-lives:

  • Canrenone: 16.5 hours 1, 2
  • 7-α-(thiomethyl) spironolactone (TMS): 13.8 hours 1, 2
  • 6-ß-hydroxy-7-α-(thiomethyl) spironolactone (HTMS): 15 hours 1

Clinical Implications of Spironolactone's Half-Life

Dosing Considerations

  • Despite the short half-life of the parent compound, the long half-life of the active metabolites allows for once-daily dosing in most clinical scenarios 3
  • Steady-state concentrations require 3-4 days to achieve due to the accumulation of active metabolites 3
  • When initiating therapy, the full clinical effect may be delayed for several days due to this pharmacokinetic profile 3

Comparison to Other Aldosterone Antagonists

  • Eplerenone has a shorter half-life than spironolactone's metabolites and does not produce active metabolites 4
  • This pharmacokinetic difference contributes to the lower incidence of hyperkalemia with eplerenone compared to spironolactone 4

Special Populations

  • The terminal half-life of spironolactone may be increased in patients with cirrhotic ascites 1
  • In infants and young children, the pharmacokinetics of spironolactone and its metabolites show high variability, with body weight explaining about 22% of this variability 5

Elimination

  • Metabolites are primarily excreted in the urine and secondarily in bile 1
  • After oral administration, approximately 31.6% of the drug is excreted in urine and 22.7% in feces over 5 days 6

The prolonged clinical effect of spironolactone, despite its short parent compound half-life, is due to the extended half-lives of its active metabolites. This explains why spironolactone can be effectively administered once daily despite the parent compound's rapid elimination.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.